These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25723326)

  • 1. [Drug delivery strategies for targeted treatment of inflammatory bowel disease].
    Lautenschläger C; Schmidt C; Lange K; Stallmach A
    Z Gastroenterol; 2015 Mar; 53(3):226-34. PubMed ID: 25723326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug delivery strategies in the therapy of inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Fischer D; Stallmach A
    Adv Drug Deliv Rev; 2014 May; 71():58-76. PubMed ID: 24157534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease.
    Guo Y; Zong S; Pu Y; Xu B; Zhang T; Wang B
    Molecules; 2018 Jul; 23(7):. PubMed ID: 29973488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
    Kesisoglou F; Zimmermann EM
    Expert Opin Drug Deliv; 2005 May; 2(3):451-63. PubMed ID: 16296767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.
    Wolk O; Epstein S; Ioffe-Dahan V; Ben-Shabat S; Dahan A
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1275-86. PubMed ID: 23721560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies.
    Talaei F; Atyabi F; Azhdarzadeh M; Dinarvand R; Saadatzadeh A
    Eur J Pharm Sci; 2013 Jul; 49(4):712-22. PubMed ID: 23665411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.
    Youshia J; Lamprecht A
    Expert Opin Drug Deliv; 2016; 13(2):281-94. PubMed ID: 26637060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New oral delivery systems for treatment of inflammatory bowel disease.
    Friend DR
    Adv Drug Deliv Rev; 2005 Jan; 57(2):247-65. PubMed ID: 15555741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [DDS preparations of drugs for inflammatory bowel disease].
    Takada K
    Nihon Rinsho; 1999 Nov; 57(11):2508-15. PubMed ID: 10572421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
    Klotz U; Schwab M
    Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
    Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
    Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update.
    Dahan A; Amidon GL; Zimmermann EM
    Expert Rev Clin Immunol; 2010 Jul; 6(4):543-50. PubMed ID: 20594127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional drug therapy for inflammatory bowel disease.
    Bryant RV; Brain O; Travis SP
    Scand J Gastroenterol; 2015 Jan; 50(1):90-112. PubMed ID: 25523560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
    Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
    J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 19. Current stage in inflammatory bowel disease: What is next?
    Gómez-Gómez GJ; Masedo Á; Yela C; Martínez-Montiel Mdel P; Casís B
    World J Gastroenterol; 2015 Oct; 21(40):11282-303. PubMed ID: 26525013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
    Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
    Scand J Gastroenterol; 2019 Jan; 54(1):18-26. PubMed ID: 30678499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.